Efficacy, safety and cost of Qianlieshutong Capsules in the treatment of chronic prostatitis.
- Author:
Chang LIU
1
;
Ting-Ting JIANG
1
;
Cong ZHANG
1
;
Hai-Liang GAO
1
;
Si-Yue WANG
1
;
Meng-Pei ZHANG
1
;
Zhi-Heng WANG
1
;
Hao-Xiang ZHANG
1
;
Wen-Tao ZHU
1
Author Information
1. School of Management, Beijing University of Chinese Medicine, Beijing 100029, China.
- Publication Type:Journal Article
- Keywords:
Qianlieshutong Capsules;
chronic prostatitis;
meta-analysis;
quinolones
- From:National Journal of Andrology
2019;25(5):444-450
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To comprehensively evaluate the clinical effect, safety and cost of Qianlieshutong Capsules (QC) in the treatment of chronic prostatitis.
METHODS:We searched Cochrane Library, PubMed, Springer, ProQuest, CNKI, Wanfang Data and VIP for randomized controlled trials (RCT) on the treatment of chorionic prostatitis with QC published from January 2000 to May 2018. According to the inclusion and exclusion criteria, two researchers independently completed the screening and evaluation of the articles, extraction of information, and meta-analysis of the included RCTs using the RevMan 5.3 software.
RESULTS:Totally 10 RCTs involving 1 796 cases were included in this study, in which the chronic prostatitis patients treated by the combination of QC and quinolones all showed a significantly better response than the controls (P < 0.05). QC combined with quinolones cost an average of ¥23 more than quinolones alone with a 1% increase of therapeutic effectiveness, ¥38.39 more with a 1-unit reduction of WBCs, and ¥38.84 more with a 1-point decrease in the NIH-CPSI score.
CONCLUSIONS:The combination of QC with quinolones has a better therapeutic efficacy but a higher cost than quinolones alone in the treatment of chronic prostatitis.
